Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

of this product franchise.

-- Sales of Sepra(R) products continued to be strong, rising 32 percent to

$30.6 million in the first quarter from $23.1 million in the same

quarter a year ago. The expanded U.S. sales force for Seprafilm(R)

adhesion barrier is reaching a broader range of physicians and helping

drive the product's growth in gynecologic and colorectal surgery.

Future growth of the product in C-section procedures and trauma

surgeries is expected.

-- First-quarter revenue for the Genetics business increased 12 percent to

$74.3 million from $66.2 million, fueled substantially by a higher

volume of reproductive diagnostic testing. The profitability of the

Genetics business is also increasing through improvements in operating

efficiencies, while Genzyme continues to invest in additional

information technology and infrastructure to strengthen the competitive

advantages the business has created. Genzyme Genetics recently

launched carrier and prenatal diagnostic testing for spinal muscular

atrophy, the most common inherited cause of infant mortality. These

tests are expected to support continued profitable growth in subsequent

quarters.

-- Oncology revenue increased 29 percent in the first quarter to $29.0

million from $22.4 million. This growth primarily reflects the

addition of European sales of Clolar, which Genzyme began recording

following its acquisition of Bioenvision Inc. late last year. Genzyme

is working to introduce Clolar worldwide through its global commercial

and regulatory organization. Oncology revenue also reflects growing

first-line use of Campath(R) (alemtuzumab) in the treatment of patients

with B-cell chronic lymphocytic leukemia.

Late-State Development Programs

Genzyme continues to make strong prog
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 , Todd Martensen ... Mariano Rodríguez es elegid vicepresidente senior de desarrollo ... está en marcha para comenzar de forma rápida la comercialización ... reciente aprobación en Europa   , ... anunciar los siguientes nombramientos: Todd Martensen ...
(Date:11/21/2014)... 2014 Author Matthew J. Pallamary’s second ... Other Side” published as a tribute to his ... “Fiction: Short Story” category of the 2014 USA ... CEO of USA Book News, said this year’s contest ... including Simon & Schuster, Penguin, John Wiley & Sons, ...
(Date:11/21/2014)... 20, 2014 BlueInGreen, LLC ( ... LLC (Pinnacle), and PCI, Inc., leading suppliers of ... have been selected to provide a new state-of-the-art ... Paul R. Noland Wastewater Treatment. The new ... HyDOZ® gas dissolution technology, Pinnacle Ozone’s industry ...
(Date:11/21/2014)... Nov. 20, 2014 Polaris Group announced ... in its Phase 1 trial of ADI-PEG 20 ... treatment of malignant pleural mesothelioma (MPM) and non-squamous ... clinical trials on ADI-PEG 20, both as monotherapy ... treatment of several other indications, including breast cancer, ...
Breaking Biology Technology:KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... (Nasdaq: EXEL ) today announced the closing of ... net proceeds of the,offering are approximately $71.8 million, after ... offering are being sold by,Exelixis. Exelixis has also granted ... additional 1,050,000 shares of common stock. Goldman,Sachs & Co. ...
... Total Site Solutions,(TSS), a Fortress International Group ... for the planning, design and development of,mission-critical facilities ... biotech industry has awarded them the construction,management phase ... originally performed technology consulting services to analyze,short term ...
... Colo., Sept. 13 Allos,Therapeutics, Inc. (Nasdaq: ... and commercialization of small molecule therapeutics for,the treatment ... President and,CEO, will present a corporate overview at ... York. The Company,s presentation will take place ...
Cached Biology Technology:Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 2Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 3Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference 2
(Date:11/4/2014)... Nov. 4, 2014   Neurotechnology , a ... that the latest version of its fingerprint matching ... Ongoing MINEX evaluation organized by NIST. The ... using the INCITS 378 fingerprint standard template format. ... public tenders in the United States ...
(Date:11/3/2014)... study published in this month,s Proceedings of ... of a recently discovered communication molecule of the body,s ... known to limit inflammation and the current study reports ... the ability of the immune system to recognize and ... IL-37,s effect on the immune system now allows us ...
(Date:11/3/2014)... that low birth weight and preterm birth are linked ... adulthood. Findings published in the American College of Rheumatology ... that low birth weight and pre-term babies were not ... as adults. , According to the ACR, 27 ... with clinical OA. Symptoms of OA range from mild ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2
... of UK researchers, funded by the Biotechnology and Biological ... sequence coverage of the wheat genome. The release is ... a significant contribution to efforts to support global food ... The genome sequences released comprise five read-throughs of ...
... , BLOOMINGTON, Ind. -- The next generation of neutron ... million boost from the National Institute for Standards and ... $1 million a year for five years to support ... (LENS) at IU Bloomington and NIST,s National Center for ...
... and beta-carotene supplements are unsafe for HIV-positive women who ... in breast milk---thereby increasing the chances of transmitting the ... suggest. Epidemiologist Eduardo Villamor of the University of ... through breastfeeding happens because breast milk carries viral particles ...
Cached Biology News:UK researchers release draft sequence coverage of wheat genome 2UK researchers release draft sequence coverage of wheat genome 3IU physics facility awarded $5 million for cooperative neutron research 2Vitamin A increases the presence of the HIV virus in breast milk 2
...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Harmful, Irritant, Combustible ,DEPC...
Cytofix Buffer 100 mls...
Biology Products: